EUDA Health Holdings Limited Has Received Notice from Nasdaq that it has Failed to Maintain a Minimum Market Value of its Listed Securities
Rhea-AI Summary
EUDA Health Holdings (NASDAQ:EUDA) received a Nasdaq notice dated April 23, 2026, that it failed to maintain a $35.0 million Minimum Market Value of Listed Securities (MVLS) over the last 32 consecutive business days.
The MVLS notice does not affect the current listing immediately. The company has a 180-calendar-day compliance period ending October 20, 2026, to close at $35,000,000 or more for ten consecutive business days to regain compliance; failure could lead to delisting proceedings and a possible appeal.
Positive
- Nasdaq provided a 180-calendar-day compliance period ending Oct 20, 2026
- The MVLS notice has no immediate effect on the company’s Nasdaq listing
Negative
- Company failed to meet the $35,000,000 MVLS requirement over 32 business days
- Failure to regain compliance could trigger delisting proceedings
- Company must achieve MVLS ≥ $35,000,000 for ten consecutive business days
News Market Reaction – EUDA
In the Apr 27 session, EUDA gained 21.09%, reflecting a significant positive market reaction. Argus tracked a peak move of +62.4% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 19 | Reverse stock split | Negative | -15.2% | Announced 1-for-20 reverse split to consolidate outstanding ordinary shares. |
| Mar 04 | Warrant repurchase | Positive | -2.7% | Repurchased and cancelled Streeterville warrant, eliminating up to 2,000,000 dilution shares. |
| Jan 15 | Warrant amendment | Negative | -4.2% | Cut Streeterville warrant exercise price to US$2.00, easing forced-exercise price to US$3.00. |
| Jan 13 | Convertible loan deal | Neutral | -13.9% | Convertible loan up to RMB 6 million to fund Shenzhen cGMP facility upgrade. |
| Jan 07 | Warrant amendment | Negative | +5.7% | Reduced warrant exercise price from US$6.00 to US$4.00 and lowered forced-exercise trigger. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent EUDA news related to capital structure, warrants, and financing has frequently coincided with negative price reactions, even when actions reduced potential dilution. The market has tended to respond bearishly to both balance-sheet adjustments and strategic financing moves, suggesting a cautious stance toward corporate actions affecting equity value.
Over the past six months, EUDA has focused on capital structure changes and financing. A 1-for-20 reverse split on Mar 23, 2026 and multiple Streeterville warrant amendments adjusted exercise prices and potential dilution, with mixed immediate reactions. The company also repurchased and cancelled a warrant for US$125,000, removing up to 2,000,000 potential shares, and entered a convertible loan agreement of up to RMB 6 million to support a Shenzhen cGMP upgrade. The current Nasdaq MVLS deficiency notice adds listing-risk pressure on top of this capital structure backdrop.
Key Terms
market value of listed securities regulatory
delisting regulatory
nasdaq capital market regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Singapore, April 27, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice (the “MVLS Notice”) from Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) on April 23, 2026, indicating that the Company had failed to maintain a Minimum Market Value of Listed Securities (“MVLS”) of
The MVLS Notice has no immediate effect on the listing of the Company’s securities on Nasdaq and the Company has been provided a period of 180 calendar days from the date of the MVLS Notice, or until October 20, 2026, in which to regain compliance (the “MVLS Compliance Period”). In order to regain compliance with Nasdaq Listing Rule 5550(b)(2), the Market Value of Listed Securities of the Company must close at
In the event that the Company does not regain compliance with Nasdaq Listing Rule 5550(b)(2) within the MVLS Compliance Period, Nasdaq will provide notice to the Company that its listed securities will be subject to delisting. In the event of such notification, the Company may appeal Nasdaq’s determination to delist its securities. However, there can be no assurances that Nasdaq would be able to regain compliance with all applicable requirements for continued listing on the Nasdaq Capital Market.
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than
Forward-Looking Statements
This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
For investor and media inquiries, please contact:
Christensen Advisory
Christian Arnell
Phone: +852 2117 0861
Email: christian.arnell@christensencomms.com
